NVAX Q4 2019 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+43.9% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$29M-325.6% margin

Net Income

-$32M-361.0% margin

EPS (Diluted)

$-1.13

QoQ Revenue Growth

+251.7%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$173M

Total Liabilities

$359M

Stockholders' Equity

-$186M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$6M	+43.9%
Gross Profit	$9M	$6M	+43.9%
Operating Income	-$29M	-$47M	+38.3%
Net Income	-$32M	-$49M	+35.5%

Revenue Segments

Grant

$1M100%